Why the study?
Does the use of heparin-coated circuits improve biocompatibility in pediatric patients undergoing cardiopulmonary bypass?
Does the use of heparin-coated circuits improve biocompatibility in pediatric patients undergoing cardiopulmonary bypass?
Heparin-coated CPB circuits reduce complement activation and inflammatory markers in pediatric patients, suggesting superior biocompatibility.
Heparin-coated circuits were associated with lower inflammatory markers in pediatric CPB; leaves open effects on clinical outcomes and warrants randomized trials.
In this study, we evaluated the biocompatibility of heparin-coated circuits in pediatric cardiopulmonary bypass (CPB). Eight patients were divided into 2 groups: the control group (Group C) and heparin-coated group (Group H). In Group H, CPB circuits, including the arterial pump, oxygenator, and cannulas were heparin-coated. Before, during, and after CPB, blood samples were obtained to assess the platelet counts (Plat), alpha 2-plasmin plasminogen inhibitor complex (PIC), thrombin-antithrombin III complex (TAT), C3 activation products (C3a), interleukin (IL)-6, IL-8, and polymorphonuclear neutrophil leukocyte (PMN) elastase. There was no significant difference in Plat, PIC, or TAT between groups. Group H showed significantly low levels of C3a (during and after CPB), PMN elastase (during CPB), and IL-6 (after CPB). These data demonstrated that in pediatric CPB, heparin-coated CPB circuits reduced the activation of complements and the production of PMN elastase and IL-6, suggesting the superior biocompatibility of the heparin-coated circuits.
No takes yet. Share an insight, caveat, or question.
Kagisaki et al. (1997) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: